NASDAQ$APGE
Apogee Therapeutics Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Apogee Therapeutics reported Q3 2025, a net loss of $65M.
For Q3 2025, Apogee Therapeutics reported a net loss of $65M. Management discusses operating trends, liquidity, and strategic priorities as disclosed in the quarterly filing.
- Net loss $65M.
- Apogee Therapeutics updated clinical, capital, or portfolio priorities in the filing.
- Apogee Therapeutics updated clinical, capital, or portfolio priorities in the filing.
Headline financials
Revenue & EPS history
Apogee · Revenue · Quarterly
$0
Forward guidance
Management discusses Apogee Therapeutics's outlook, capital deployment, and key risks as disclosed in the earnings materials and periodic report.
Tailwinds
- Apogee Therapeutics cited progress on strategic priorities in the quarterly filing.
- Liquidity and balance sheet support continued operations and investment.
Headwinds
- GAAP profitability remained under pressure in the reported quarter.
- Macro, competitive, and regulatory factors may affect near-term results.
- R&D, credit, or project timing can create quarter-to-quarter volatility.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q3 2025
+5.6%
Avg return
Earnings day
+9.2%
Avg return
5 days after
+10.9%
Avg return
30 days after
53%
8 / 15 earnings
Positive
+59.8%
Q4 2023
Best reaction
-12.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.2% | +4.4% | +20.3% | |
| Q3 2025 | +3.8% | +19.7% | +39.0% | |
| Q2 2025 | -2.2% | +5.4% | +5.9% | |
| Q1 2025 | -0.0% | -1.1% | +9.4% | |
| Q4 2024 | -0.2% | +14.9% | +20.3% | |
| Q3 2024 | -12.7% | -21.8% | -26.7% | |
| Q2 2024 | +9.7% | +11.7% | +25.0% | |
| Q1 2023 | +1.5% | -5.5% | -16.7% | |
| Q1 2024 | +1.5% | -5.5% | -16.7% | |
| Q4 2023 | +59.8% | +61.8% | +41.4% | |
| Q3 2023 | +12.8% | +20.6% | +45.9% | |
| Q3 2022 | +12.8% | +20.6% | +45.9% | |
| Q4 2022 | -1.1% | +4.0% | -9.6% | |
| Q2 2022 | -1.1% | +4.0% | -9.6% | |
| Q2 2023 | -1.1% | +4.0% | -9.6% | |
| Q1 2022 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro